Development and Technology Transfer of Haemophilus influenzae type b Conjugate Vaccines for Developing Countries
This article, published in Vaccine, describes the development of a Haemophilus influenzae type b (Hib) conjugate vaccine at the National Institute for Public Health and the Environment/Netherlands Vaccine Institute (RIVM/NVI), and the subsequent transfer of its production process to manufacturers in developing countries. To address the problem of high prices and limited supplies of Hib conjugate vaccines, RIVM/NVI developed a robust Hib conjugate vaccine production process based on a proven model and transferred this technology to several partners in India, Indonesia, Korea, and China. This effort has translated into an increased and sustainable supply of affordable Hib conjugate-containing combination vaccines to make them more accessible to low-resource countries.
Author(s): Beurret M, Hamidi A, Kreeftenberg H
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Beurret M, Hamidi A, Kreeftenberg H. Development and Technology Transfer of Haemophilus influenzae type b Conjugate Vaccines for Developing Countries. Vaccine. 2012;30(33):4897-4906.